ICLR News and Press, ICON plc From 11/14/22

Summary ICON Plc has faced heavy selling pressure in FY22 amid the broad selloff in equities. There's conflicting information whether its latest rally is extendable beyond previous highs. Q3 numbers weren't supportive with cash earnings tightening and ROIC a negative spread be...

BofA Securities has upgraded contract research organization ICON plc ( ICON ) to buy from neutral citing the integration of PRA Health Sciences and confidence in core growth. The firm lowered its price target to $260 from $265 (~33% upside based on Tuesday's close). Analys...

ICON Public Limited Company (ICLR) Q3 2022 Earnings Conference Call November 03, 2022 08:00 AM ET Company Participants Kate Haven - Vice President of Investor Relations Brendan Brennan - Chief Financial Officer Steve Cutler - Chief Executive Officer Confere...

The following slide deck was published by ICON Public Limited Company in conjunction with their 2022 Q3 earnings call. For further details see: ICON Public Limited Company 2022 Q3 - Results - Earnings Call Presentation

Icon press release ( NASDAQ: ICLR ): Q3 GAAP EPS of $1.94 beats by $0.12 . Revenue of $1.94B (+3.7% Y/Y) beats by $10M . Adjusted EBITDA of $379.6 million or 19.5% of revenue, a year on year increase of 16.9%. YTD adjusted EBITDA of $1,074.5 million or 18.6% of...

Highlights Net business wins in the quarter of $2,351 million; a net book to bill of 1.21, and 1.24 on a trailing twelve month basis. Closing backlog of $20.2 billion, an increase of 1.3% on Q2 2022 or an increase of 9.0% on Q3 2021. Quarter 3 revenue of $1,942.4 milli...

Icon ( NASDAQ: ICLR ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, after market close. The consensus EPS Estimate is $2.94 (+15.3% Y/Y) and the consensus Revenue Estimate is $1.93B (+3.2% Y/Y). Over the last 2 years, ICLR has beaten EPS es...

Ireland-based Icon ( NASDAQ: ICLR ) on Thursday said it had been selected by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial evaluating a vaccine for anthrax. "BARDA is providing funding to the Government and Public Healt...

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it has been selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Respons...

Summary BAMCO’s 13F portfolio value decreased from $40.75B to $31.14B this quarter. Ron Baron increased SiteOne Landscape, ASGN, and Floor & Décor Holdings while reducing Taiwan Semi, Marriott Vacations Worldwide, and PENN Entertainment. Their top five position...